AbbVie Inc (ABBV)vsXeris Pharmaceuticals Inc (XERS)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
XERS
Xeris Pharmaceuticals Inc
$6.53
-1.51%
HEALTHCARE · Cap: $1.14B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 21425% more annual revenue ($62.82B vs $291.85M). ABBV leads profitability with a 5.8% profit margin vs 0.2%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
XERS
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Margin of Safety
+4.7%
Fair Value
$7.25
Current Price
$6.53
$0.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Revenue surging 42.8% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.2% margin — thin
Trading at 81.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 42.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while XERS is a hypergrowth play — different risk/reward profiles.
XERS carries more volatility with a beta of 0.92 — expect wider price swings.
XERS is growing revenue faster at 42.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 40/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Xeris Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?